MUC16 and cancer: This study was primarily designed to identify novel EOC biomarker candidates using the CA19-9 antigen capture approach to seek further improvement of detection of early EOC stages or histotypes that are missed with the traditional CA125 or its STn glycovariants either due to representing non expression cancers) or testing negative due to blocking by autoantibodies33.